Navigation Links
Determining genetic signature of lung tumors can help guide treatment
Date:5/20/2008

The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed. While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC), additional research is required before such a strategy can be used for routine treatment planning. The report appears in the May 20 Journal of Clinical Oncology.

This is a pivotal clinical trial that demonstrates the power of personalized medicine in lung cancer treatment, says Lecia Sequist, MD, MPH, of the MGH Cancer Center, who led the study. It is an exciting glimpse into what we hope is the future of cancer care. Instead of a one size fits all therapy, we are moving towards finding the best treatment for each patient.

The most common form of lung cancer, NSCLC is the leading cause of cancer deaths in the U.S. Until recently, there were no treatment options for NSCLC patients in whom chemotherapy failed. Iressa, which disables the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, was approved in 2003 for treatment of NSCLC even though it shrank tumors in less than 15 percent of patients because, in those whom it did help, responses were rapid and dramatic.

In 2004 MGH Cancer Center researchers and a team from Dana-Farber Cancer Institute both discovered why Iressas success was confined to a limited group of patients. Specific EGFR mutations that were probably responsible for a tumors development also made the cancer sensitive to Iressa treatment. Subsequent to that announcement, the Laboratory for Molecular Medicine at the Harvard-Partners Center for Genetics and Genomics developed a test to screen for these sensitizing mutations.

Late in 2004 a collaborative gr
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
2. New method proposed for determining which patients should get treatment for colorectal cancer
3. CSHL scientists make progress in determining how the brain selectively interprets sound
4. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
5. Will lung cancer recur? A genetic test may provide the answer
6. Genetic loci assigned for musical aptitude in Finnish families
7. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
8. Genetic links to impaired social behavior in autism
9. Genetic Engineering and Biotechnology News reports on early ADMET use
10. Combined physical and genetic map finds cancers ignition key
11. Research program focuses on genetic mutations and cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... have found a novel approach to treating cancer - ... edition of Science Translational Medicine shows that ... sent by nerves that are linked to cancer stem ... of Botox made the treatment cheap, safe and efficient. ... mice, and will soon start testing on humans. , ...
(Date:8/20/2014)... 2014 Quincy Bioscience, a Wisconsin-based biotech ... of the fastest growing private companies in the ... No. 2,941, Quincy Bioscience is honored again to be ... States. , Quincy Bioscience is manufacturer of Prevagen brand ... protein originally discovered in jellyfish and clinically shown to ...
(Date:8/20/2014)... DALLAS (PRWEB) August 20, 2014 Caddis ... track records of any healthcare real estate company in ... of medical assets valued at $500 million, including more ... of that significant growth, including expansions into new geographic ... expanded capabilities, company executives are pleased to announce an ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Braverman Eye ... the help of their experienced surgeons trained in PresbyLasik. ... to regain their lost or inaccurate vision. Their diligent ... Lasik surgery is making it possible for Presbyopia patients ... which occurs normally in people in the age group ...
(Date:8/20/2014)... August 20, 2014 Texas Medical Research Associates ... The study will help test the effectiveness of a new ... high cholesterol may be eligible to participate in the study. ... in the blood can lead to cardiovascular disease, the no. ... can help reduce the risk of heart disease and stroke. ...
Breaking Medicine News(10 mins):Health News:Treating gastric cancer -- with Botox 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2Health News:Texas Medical Research Associates Announce New Study 2
... Jenifer Goodwin HealthDay Reporter , TUESDAY, June ... U.S. Preventive Services Task Force recommendations that women in ... and furious. Using email, social networking sites and electronic ... , Researchers say the magnitude of the reaction heralded ...
... have discovered a potent and highly-debilitating toxin in the ... is now prompting investigations of other marine mammals in ... by marine algae common on coral reefs, and accumulates ... the human disease caused by ciguatoxin, affects thousands of ...
... of Technology & Innovation, Proceedings of the National ... future and enormous need for stem cell therapeutics that ... deadly diseases. http://www.ingentaconnect.com/content/cog/ti/2011/00000013/00000001 ... replacement" procedures to restructure damaged organs, tissues and cells, ...
... IN THE ICU , Intensive care units are ... the future. A recent study, conducted by physicians from ... in New York, NY, studying 590 daytime admissions in ... can help address these staff shortages. In the ...
... consume an average of 13 hours of media content a ... according to a Northwestern University report, the first national study ... ethnicity. "In the past decade, the gap between minority ... and quadrupled for Hispanics," says Northwestern Professor Ellen Wartella, who ...
... Cincinnati (UC) Department of Emergency Medicine has received a ... to study the implementation of electronic health records in ... support the work of Michael Ward, MD, an assistant ... the past year focusing on simulation modeling in operations ...
Cached Medicine News:Health News:Is Social Networking Changing the Face of Medicine? 2Health News:Is Social Networking Changing the Face of Medicine? 3Health News:The future of stem cell applications challenging, bright 2Health News:Chest journal news briefs -- June 2011 issue 2Health News:Study: Stark differences in media use between minority and white youth 2Health News:Study: Stark differences in media use between minority and white youth 3Health News:Study: Stark differences in media use between minority and white youth 4Health News:Using simulation to model the implementation of electronic health records 2
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... announces that a new market research report is ... Degeneration Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of macular degeneration ...
... Allscripts (NASDAQ: MDRX ) announced today that it ... March 31, 2011 after the stock market closes on Thursday, ... and webcast to discuss the company,s earnings and other information ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) More ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: